Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-011 - Observational study of treatment of epidermal growth factor receptor activating mutation positive (EGFRm+) advanced or recurrent non-small-cell lung cancer (NSCLC), after radiological progression to the first-line therapy with EGFR tyrosine kinase inhibitors (EGFR-TKI).
09:30 - 09:30 | Author(s): H. Kunitoh
- Abstract
Loading...
-
+
P1.12 - Poster Session 1 - NSCLC Early Stage
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 23
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.12-003 - Preoperative neutrophil and lymphocyte counts are independent prognostic factors in completely resected non-small cell lung cancer
09:30 - 09:30 | Author(s): N. Kobayashi
- Abstract
Loading...
-
+
P2.02 - Poster Session 2 - Novel Cancer Genes and Pathways
- Type: Poster Session
- Track: Biology
- Presentations: 21
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.02-009 - Expression of a splicing variant of the CADM1 specific to small cell lung cancer
11:46 - 12:03 | Author(s): S. Kikuchi
- Abstract
Loading...
-
+
P2.10 - Poster Session 2 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.10-022 - Prospective observational cohort study of second-line chemotherapy administration after first-line platinum-based chemotherapy for patients with advanced NSCLC in Japan (SAPPHIRE study)
09:30 - 09:30 | Author(s): Y. Goto
- Abstract
Loading... -
+
P2.10-045 - Phase II study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (Bev) as first line therapy for non-squamous non small cell lung cancer (NSCLC) without EGFR Mutation. Central Japan Lung Study Group (CJLSG) 0909 trial.
09:30 - 09:30 | Author(s): Y. Goto
- Abstract
Loading...
